<DOC>
	<DOCNO>NCT02224833</DOCNO>
	<brief_summary>PHARM-PC study base identify potentially inappropriate prescription ( PIP ) delivery therapeutic appropriateness recommendation pharmacist physician drug prescribe elderly polypharmacy patient primary care . Assessment impact pharmacist intervention appropriateness prescribe health outcome economic outcome do .</brief_summary>
	<brief_title>Inappropriate Prescription Elderly Polypharmacy Patients Primary Care ( PHARM-PC ) Trial</brief_title>
	<detailed_description>Main objective : To assess effect Pharmaceutical Intervention ( PI ) PIP elderly patient polypharmacy PC . Secondary objective : 2. a. Assess baseline characteristic elderly polypharmacy patient PC ; ass association possible presence PIP . 2. b . Describe main type reason PIP . 3 . Assess impact PI health outcome ( morbidity mortality ) . 4 . Estimate effect IF cost drug healthcare resource . Design method : Prospective , multicenter , open-label , control randomize group ( cluster ) clinical trail ; order prevent contamination Intervention Group ( IG ) Control Group ( CG ) patient see physician . Clusters ( unit randomization ) primary care physicians work public primary care health center Tramuntana Sector ( Hospital Comarcal de Inca ) . Different cluster randomly assign Intervention Group ( IG ) control group ( CG ) ratio 1 : 1 . The study compare effectiveness strategy health care elderly patient polypharmacy PC consist medical visit along PI , consistent turn identify PIP deliver therapeutic appropriateness recommendation routine health care , consist solely medical visit . Furthermore impact treatment health outcome , drug health service cost also assess . Methodology : Intervention Group : - Systematic review treatment : * Identification reason PPI : Causes pharmacological prescription ( drug , dose , route administration , duration treatment ) may risk-benefit balance cost-effectiveness balance unfavorable versus alternative , : - contraindication , dosage ( dose , frequency , duration , inappropriate ) , duplication , interaction , risk adverse effect , health problem insufficiently treat , unnecessary medication ; equivalent Drug-Related Problems ( DRP ) list Third Consensus Granada . To identify DRP use combination explicit criterion ( STOPP / START ) implicit criterion ( information : drug label , drug-surveillance alert issue drug regulatory agency , recommendation scientific society ) ; implement CheckTheMeds® software . - Drugs cost-effective alternative , rank Committee Quality Indicators Prescription Health Service Balearic Islands : - New drug little therapeutic value : drug market past 5 year consider `` Comité Mixto de Evaluación de Nuevos Medicamentos '' little therapeutic value alternative available market treatment pathology : metformin / saxagliptin , linagliptin / metformin , saxagliptin , linagliptin , rosuvastatin , pitavastatin , sinecatequin , ingenol mebutate , bazedoxifene , silodosin , degarelix , denosumab , hydromorphone , tapentadol , agomelatine , desvenlafaxine , indacaterol , ciclesonide , aclidinium bromide , glycopyrronium bromide , roflumilast , bilastine , tafluprost . - Medications consider first choice treatment prevalent disease outpatient setting : Omeprazole ( antiulcer ) ; Metformin ( oral antidiabetic ) ; ACE inhibitor ; Beta-blockers ; diuretic ; Calcium-antagonists ( anti-hypertensive ) ; Simvastatin ( statin ) ; diclofenac ; Diclofenac / Misoprostol ; ibuprofen ; Naproxen ( anti-inflammatory drug ) ; Alendronic acid ( osteoporosis ) ; fluoxetine ; citalopram ; paroxetine ; Sertraline ( antidepressant ) . - Determination recommend pharmacotherapeutic alternative . - Issue recommendation therapeutic appropriateness doctor ( via registration EHR verbal communication deem appropriate ) ; 4 type : Add medicine ; discontinue medicine ; adjust dosage ; replace medicine . - After medical visit ( next day ) : New treatment review : checking acceptance rejection recommendation issue ; review potential new prescription make without pharmacist recommending , whether new drug lead PIP . Control Group : In control group , step follow intervention group ; exclude issue recommendation therapeutic appropriateness doctor . Sample size statistical power : The sample size calculate compare proportion use application determination sample size available Fisterra website ; base result pilot study , yet publish , show difference 15 percent number patient PIP IG CG base study Delgado et al , considers cost effective screen tool achieves least moderate reduction ( 10-20 percent ) PIP . For power 80 % , assume loss rate 10 percent ; obtain sample size 153 . Considering adjustment cluster effect , accord follow formula : 1 + ( - 1 ) x ρ , obtain final sample size 214 patient . Statistics : - Categorical variable ( qualitative ) : Measurements frequency percentage . The association categorical variable perform chi-square Fischer 's exact test ; accordingly . - Continuous Variables ( Quantitative ) : Measures central tendency dispersion measure . The association continuous variable perform use T-Student test ; ANOVA ; Mann-Whitney Kruskal-Wallis , appropriate . A value p ≤ 0.05 statistically significant consider . Timescale : The study begin October 2014 end April 2016 . Is expected patient enrol study October 2014 April 2015 , complete sample size require . The study last 12 month assess outcomes morbidity , mortality cost health care resource Ethics safety : The Research Ethics Committee Primary Care Research Unit Balearic Islands approve project .</detailed_description>
	<criteria>age ≥ 65 year treatment 5 chronic medication . routine monitoring carry private health care temporary displace person ( routine monitoring carry another community ) . Institutionalized patient Patients Home Care Program</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>appropriateness</keyword>
	<keyword>elderly</keyword>
	<keyword>polypharmacy</keyword>
	<keyword>primary care</keyword>
</DOC>